Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Net Income (2016 - 2025)

Historic Net Income for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$67.3 million.

  • ImmunityBio's Net Income rose 2154.82% to -$67.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$348.7 million, marking a year-over-year increase of 4068.11%. This contributed to the annual value of -$413.6 million for FY2024, which is 2915.24% up from last year.
  • Latest data reveals that ImmunityBio reported Net Income of -$67.3 million as of Q3 2025, which was up 2154.82% from -$92.6 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Net Income ranged from a high of -$59.2 million in Q4 2024 and a low of -$233.4 million during Q4 2023
  • Its 5-year average for Net Income is -$108.1 million, with a median of -$95.6 million in 2023.
  • Its Net Income has fluctuated over the past 5 years, first plummeted by 11547.37% in 2023, then soared by 7464.63% in 2024.
  • Quarter analysis of 5 years shows ImmunityBio's Net Income stood at -$91.6 million in 2021, then fell by 18.32% to -$108.3 million in 2022, then tumbled by 115.47% to -$233.4 million in 2023, then surged by 74.65% to -$59.2 million in 2024, then fell by 13.68% to -$67.3 million in 2025.
  • Its Net Income stands at -$67.3 million for Q3 2025, versus -$92.6 million for Q2 2025 and -$129.7 million for Q1 2025.